Not yet recruiting
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:”
“A multi-arms prospective, randomized phase II study to evaluate the best sequential
therapeutic strategis in patients with metastatic non-small cell lung cancer harboring
targetable genomic driver alterations”
2026-525268-16-00· Phase 2/3· Universita' Degli Studi Di Torino· Source
Not yet recruiting
triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
NCT07440381· Phase 3· Heart Care Foundation· Source
Recruiting
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
2025-521666-10-01· Phase 2· Fondazione Italiana Linfomi Ets· Source
Recruiting
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
NCT07554495· Phase 3· Alfasigma S.p.A.· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4
NCT07522697· Phase 2· National Cancer Institute, Naples· Source
Recruiting
OLE Study With Filgotinib in JIA
NCT07553182· Phase 3· Alfasigma S.p.A.· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· Phase 3· Genmab· Source
Recruiting
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
NCT07290894· Phase 2· National Cancer Institute, Naples· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· Phase 3· BioNTech SE· Source
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer
NCT05233982· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Active, not recruiting
Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma
2023-506049-52-00· Phase 2· Fondazione Italiana Linfomi Ets· Source
Recruiting
Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism
2024-511959-18-01· Phase 3· Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal· Source
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Active, not recruiting
Multicenter, randomized, double-blind, Phase III study of intravenous TAD® 600 mg/4 ml solution for injection to evaluate efficacy and safety in preventing myocardial injury in patients with pneumonia
2023-503950-11-00· Phase 3· Biomedica Foscama Industria Chimico-Farmaceutica S.p.A.· Source
Active, not recruiting
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386· Phase 4· GlaxoSmithKline· Source
Active, not recruiting
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530· Phase 2· AstraZeneca· Source
Recruiting
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
NCT05718323· Phase 2· ETOP IBCSG Partners Foundation· Source
Recruiting
Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial.
2022-502775-29-01· Phase 3· Fondazione Italiana Linfomi Onlus· Source
Active, not recruiting
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
NCT05673187· Phase 2· ETOP IBCSG Partners Foundation· Source
Active, not recruiting
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399· Phase 3· AstraZeneca· Source
Active, not recruiting
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
NCT05249959· Phase 2· Fondazione Italiana Linfomi - ETS· Source
Recruiting
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255471· Phase 3· National Cancer Institute, Naples· Source
Active, not recruiting
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· Phase 3· Fondazione Italiana Linfomi - ETS· Source
Active, not recruiting
Pulmonary Embolism International THrOmbolysis Study-3
NCT04430569· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB study- MITO 36)
2024-518847-40-00· Phase 2· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Recruiting
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
NCT04257487· Phase 3· Arianna Anticoagulazione Foundation· Source
Recruiting
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Active, not recruiting
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
NCT03610438· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source